The armamentarium for the systemic therapy of advanced renal cell carcinoma (RCC) has
undergone dramatic changes over the past 6 years. While high-dose interleukin (IL)-2 …

Background Previous prognostic models for second-line systemic therapy in patients with
metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We …

Multiple targeted agents are now available for the treatment of patients with metastatic renal
cell carcinoma (mRCC). Although targeted agents offer improvements over previous …

Background A subset of patients treated with initial anti-vascular endothelial growth factor
(VEGF) therapy exhibit progressive disease (PD) as the best response per RECIST criteria …

Renal cell carcinoma (RCC) is the most common neoplasm of adult kidney. One of the
important unmet medical needs in RCC is prognostic biomarker enabling identification of …

Background To estimate, from the perspective of the Chinese healthcare system, the
economic outcomes of five different first-line strategies among patients with metastatic renal …

AIM: A number of targeted therapies (TTs) are effective in metastatic renal cell carcinoma
(mRCC) but clinical outcomes with the sequential use of three TTs have been poorly …

CONTEXT: The expanding armamentarium of agents for the therapy of advanced clear cell
renal cell carcinoma (RCC) warrants further investigation of optimal patient selection …

Targeted agents have substantially improved patient outcomes in metastatic renal cell
carcinoma (mRCC) and have now replaced cytokines as standard of care. Despite the …

With 15 drugs currently approved for the treatment of metastatic renal cell carcinoma
(mRCC) and even more combination regimens with immunotherapy on the horizon, there …